Literature DB >> 15691238

Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum.

Evangelia Daviskas1, Sandra D Anderson, Kerry Gomes, Peter Briffa, Belinda Cochrane, H-Kim Chan, Iven H Young, Bruce K Rubin.   

Abstract

OBJECTIVE: Inhaled mannitol increases mucus clearance in patients with bronchiectasis by an unclear mechanism. The effect of mannitol on lung function, health status and sputum properties was investigated.
METHODOLOGY: Nine patients with bronchiectasis inhaled 400 mg of mannitol once daily for 12 days. Health status was assessed using the St George's Respiratory Questionnaire (SGRQ). Sputum was analysed for viscosity, elasticity, spinnability, surface tension, contact angle, solids, mucociliary transportability (MCTR) on a frog palate, and cough transportability (CTR) on a simulated cough machine.
RESULTS: Lung function was unchanged with treatment (baseline FEV1 82.0 +/- 16.2%) apart from an improvement in FEF from 85.4 +/- 13% (baseline) to 90.7 +/- 14.4% (P < 0.05; 12th treatment; visit 7). The total SGRQ score (mean +/- SD) of 49.3 +/- 13.8 at baseline, decreased by 12.4 +/- 10.2 (P < 0.01; visit 7) and 10.1 +/- 9.4 units (P < 0.02) 6-10 days after treatment cessation. The baseline subscores for symptoms (72.9 +/- 11.8), activity (44.7 +/- 20.9) and impact (44.4 +/- 14.3) were reduced by 0.8 +/- 9.1 (P > 0.7), 8.4 +/- 16.0 (P > 0.1) and 19.2 +/- 13.7 (P < 0.005) units, respectively (visit 7). Mannitol reduced the baseline (mean +/- SE) surface tension from 94.5 +/- 1.4 to 84.7 +/- 2.1 mN/m (P < 0.0001), contact angle from 51.1 +/- 2.8 to 33.2 +/- 2.4 degrees (P < 0.0001), spinnability from 11.6 +/- 0.4 to 10.0 +/- 0.2 mm (P < 0.005), and solids from 5.7 +/- 0.4 to 4.3 +/- 0.7% (P < 0.02), acutely (visit 7). Viscosity, elasticity and MCTR did not change significantly, while CTR was increased from 25.8 +/- 1.0 to 34.1 +/- 2.7 mm (P < 0.003).
CONCLUSION: Mannitol significantly improved the health status over 12 days and this improvement was maintained for 6-10 days after cessation of treatment. In addition, mannitol reduced the tenacity, increased the hydration of mucus acutely and improved cough clearability in patients with bronchiectasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15691238     DOI: 10.1111/j.1440-1843.2005.00659.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  16 in total

Review 1.  [Treatment of not-with cystic fibrosis associated forms bronchiectasis (non-CF bronchiectasis)].

Authors:  J Rademacher; M W Pletz; T Welte
Journal:  Internist (Berl)       Date:  2010-12       Impact factor: 0.743

2.  Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses.

Authors:  Matthew S Coates; Hak-Kim Chan; David F Fletcher; Judy A Raper
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

Review 3.  Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents.

Authors:  Jonathan Ilowite; Peter Spiegler; Heather Kessler
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 4.  Bronchiectasis--diagnosis and treatment.

Authors:  Jessica Rademacher; Tobias Welte
Journal:  Dtsch Arztebl Int       Date:  2011-12-02       Impact factor: 5.594

5.  Neutrophilic inflammation is associated with altered airway hydration in stable asthmatics.

Authors:  Ceila E Loughlin; Charles R Esther; Eduardo R Lazarowski; Neil E Alexis; David B Peden
Journal:  Respir Med       Date:  2009-07-30       Impact factor: 3.415

6.  Bronchiectasis, part 2: Management.

Authors:  Meeta Prasad; Gregory Tino
Journal:  J Respir Dis       Date:  2008-01-01

7.  Analysis of the sputum and inflammatory alterations of the airways in patients with common variable immunodeficiency and bronchiectasis.

Authors:  Andrea Cristina Pereira; Cristina M Kokron; Beatriz Mangueira Saraiva Romagnolo; Claudia Simeire Albertini Yagi; Paulo Hilário Nascimento Saldiva; Geraldo Lorenzi Filho; Elnara Marcia Negri
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

8.  Inhaled mannitol for cystic fibrosis.

Authors:  Sarah J Nevitt; Judith Thornton; Clare S Murray; Tiffany Dwyer
Journal:  Cochrane Database Syst Rev       Date:  2020-05-01

9.  Rheological effects of hypertonic saline and sodium bicarbonate solutions on cystic fibrosis sputum in vitro.

Authors:  Mária Budai-Szűcs; Szilvia Berkó; Anita Kovács; Pongsiri Jaikumpun; Rita Ambrus; Adrien Halász; Piroska Szabó-Révész; Erzsébet Csányi; Ákos Zsembery
Journal:  BMC Pulm Med       Date:  2021-07-12       Impact factor: 3.317

10.  Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis.

Authors:  Antonello Nicolini; Federica Cardini; Norma Landucci; Sergio Lanata; Maura Ferrari-Bravo; Cornelius Barlascini
Journal:  BMC Pulm Med       Date:  2013-04-04       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.